CN116077454A - 含雌四醇组分的口腔分散剂量单位 - Google Patents
含雌四醇组分的口腔分散剂量单位 Download PDFInfo
- Publication number
- CN116077454A CN116077454A CN202310318476.9A CN202310318476A CN116077454A CN 116077454 A CN116077454 A CN 116077454A CN 202310318476 A CN202310318476 A CN 202310318476A CN 116077454 A CN116077454 A CN 116077454A
- Authority
- CN
- China
- Prior art keywords
- estetrol
- dosage unit
- weight
- combinations
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title claims abstract description 198
- 229950009589 estetrol Drugs 0.000 title claims abstract description 181
- 239000007787 solid Substances 0.000 claims abstract description 62
- 239000002245 particle Substances 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000011363 dried mixture Substances 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 39
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000000811 xylitol Substances 0.000 claims description 13
- 235000010447 xylitol Nutrition 0.000 claims description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 13
- 229960002675 xylitol Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 235000019414 erythritol Nutrition 0.000 claims description 7
- 229940009714 erythritol Drugs 0.000 claims description 7
- 238000002657 hormone replacement therapy Methods 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- 150000005846 sugar alcohols Chemical class 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 235000012222 talc Nutrition 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 239000004368 Modified starch Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 238000007907 direct compression Methods 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 239000004067 bulking agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 description 40
- 238000009472 formulation Methods 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 13
- -1 estriol compound Chemical class 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000583 progesterone congener Substances 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 4
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 4
- 229960004190 nomegestrol acetate Drugs 0.000 description 4
- 229940053934 norethindrone Drugs 0.000 description 4
- 229960001652 norethindrone acetate Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 239000006190 sub-lingual tablet Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000001457 vasomotor Effects 0.000 description 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001348 estriol Drugs 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229950008546 trimegestone Drugs 0.000 description 3
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 3
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 229960004976 desogestrel Drugs 0.000 description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960004845 drospirenone Drugs 0.000 description 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 2
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
- 229960004913 dydrogesterone Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229960005352 gestodene Drugs 0.000 description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004616 medroxyprogesterone Drugs 0.000 description 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
- ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 description 2
- 229960001566 methyltestosterone Drugs 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 229960000417 norgestimate Drugs 0.000 description 2
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 1
- KXUGUWTUFUWYRS-UHFFFAOYSA-N 1-methylimidazole-4-sulfonyl chloride Chemical compound CN1C=NC(S(Cl)(=O)=O)=C1 KXUGUWTUFUWYRS-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- ORGPUALGNXTPAW-UHFFFAOYSA-N 2,6-dichloro-n-(1-cyanocycloheptyl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1(C#N)CCCCCC1 ORGPUALGNXTPAW-UHFFFAOYSA-N 0.000 description 1
- ZMLDTNLDYRJTAZ-GDLCRWSOSA-N 3b-Hydroxydesogestrel Chemical compound O[C@H]1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ZMLDTNLDYRJTAZ-GDLCRWSOSA-N 0.000 description 1
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- 241000403354 Microplus Species 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010004978 Steroid 16-alpha-Hydroxylase Proteins 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- OMPTUWYLCDEFSJ-WAUHAFJUSA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCC)[C@@]1(C)CC2 OMPTUWYLCDEFSJ-WAUHAFJUSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003309 dienogest Drugs 0.000 description 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004805 melengestrol Drugs 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 229960003578 metenolone Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000005179 oral vestibule Anatomy 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001507 sample dispersion Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003410 testosterone decanoate Drugs 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及含雌四醇组分的口腔分散剂量单位。具体而言,本发明提供重量为30‑1000mg的口腔分散固体药物剂量单位,所述剂量单位由以下组成:0.1‑25重量%的含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒;和75‑99.9重量%的一种或多种药学上可接受的成分;所述固体剂量单位包含至少100μg的所述雌四醇组分;且其中所述固体剂量单位可以通过包括将雌四醇颗粒与一种或多种药学上可接受的赋形剂的干燥的混合物压制成固体剂量单位的方法获得。所述固体剂量单位易于制造并且非常适合于舌下、口腔或唇下给药。
Description
本申请是2016年6月17日提交的发明名称为“含雌四醇组分的口腔分散剂量单位”的中国专利申请201680035627.8的分案申请。
技术领域
本发明提供重量为30-1000mg且含有至少0.1mg的选自雌四醇、雌四醇酯及其组合的雌四醇组分的口腔分散固体药物剂量单位。该固体剂量单位由以下组成:
·0.1-25重量%的含有至少80重量%的雌四醇组分的雌四醇颗粒;和
·75-99.9重量%的一种或多种药学上可接受的成分。
本发明还提供制备上述固体剂量单位的方法。
此外,本发明涉及固体剂量单位在医学治疗、女性激素替代疗法和女性避孕中的用途,所述用途包括所述剂量单位的舌下、口腔或唇下给药。
发明背景
雌四醇是仅在妊娠期间由胎儿肝脏产生的人体类固醇。这种天然激素是在1965年由Diczfalusy及其同事在孕妇的尿液中发现的。雌四醇具有带有四个羟基的雌激素类固醇的结构。雌四醇通过15α-和16α-羟化酶两种酶在胎儿肝脏中从雌二醇和雌三醇合成。出生后新生儿肝脏迅速丧失其合成雌四醇的能力,因为这两种酶不再表达。
雌四醇通过胎盘到达母体循环,并且已经在妊娠九周时在母体尿液中检测到。在妊娠中期,在母体血浆中发现高水平,在接近妊娠结束时,未结合雌四醇的浓度稳定地升高到约1ng/mL(>3nmol/L)。到目前为止,雌四醇的生理功能是未知的。雌四醇作为胎儿健康标志物的可能用途已被相当广泛地研究。然而,由于妊娠期间母体雌四醇血浆水平的个体内和个体间的变化较大,这似乎是不可行的。
自2001年以来,雌四醇已被广泛研究。在人体中证明雌四醇具有较高且剂量成比例的口服生物利用度和约28小时的长终末消除半衰期。来自体外研究的结果显示,与雌激素乙炔雌二醇和17β-雌二醇不同,雌四醇与雌激素受体高度选择性地结合,对受体的ERα形式有偏好。同样地与乙炔雌二醇和特别是与17β-雌二醇相比,雌四醇不与性激素结合球蛋白(SHBG)结合,并且不会刺激体外SHBG的产生。
也已经在一系列预测的、经很好验证的药理学体内大鼠模型中研究了雌四醇的性质。在这些模型中,雌四醇对阴道、子宫(子宫肌膜和子宫内膜)、体重、骨量、骨强度、热潮红和排卵(抑制)表现出雌激素作用。雌四醇的所有这些作用都是剂量依赖性的,在可比较的剂量水平下具有最大作用。令人惊奇的是,在一定程度上并且在类似于抗雌激素他莫昔芬和卵巢切除术的剂量水平,雌四醇在DMBA乳腺肿瘤模型中预防了肿瘤发展。在使用人乳腺癌细胞的体外研究中也观察到雌四醇在17β-雌二醇存在下的抗雌激素作用。
包括WO 2002/094275、WO 2002/094276、WO 2002/094278和WO 2003/018026的多个专利申请中提到了雌四醇的口腔、舌下或唇下给药。这些公开中没有记载用于口腔、舌下或唇下给药的含有雌四醇的剂量单位。
WO 2010/033832记载了包含雌三醇化合物和药学上可接受的基质材料的口服剂型,其中口服剂型在与口腔和/或舌下腔的唾液接触的小于约300秒的时间内释放至少约90%的雌三醇化合物。
US 2007/286829记载了能够递送具有改善的生物利用度的乙炔雌二醇的口服给药固体剂型,所述固体剂型包含(i)约0.5μg至约50μg乙炔雌二醇和(ii)口腔溶出增强载体,其在所述固体剂型用2盎司或更少的水口服给药于患者时提供通过口腔粘膜至少15%乙炔雌二醇的吸收。
US 6,117,446记载了用于给药类固醇活性剂的组合的含服剂量单位,其包含生物可蚀解聚合载体和治疗有效量的雄激素剂(选自睾酮及其药理学可接受的酯)、黄体制剂(progestin)和雌激素的压制片剂。实施例记载了通过彻底混合以下组分制备的含服剂量单位:雌激素、孕激素、雄激素、聚环氧乙烷、卡波姆和硬脂酸镁。接着,通过流化床造粒将混合物造粒,将如此获得的粒子压制成片剂。
在几个专利公开中已经记载了含有雌四醇的口服剂量单位。
WO 2002/094276记载了用于激素替代疗法方法的药物组合物,该方法包括向需要这样的疗法的人给药有效量的雌四醇,所述组合物实际上不含有孕激素或抗黄体制剂。WO2002/094276记载了基于以下配方制备含有1.5mg雌四醇,重量为185mg的雌四醇片剂:
WO 2002/094275记载了雌四醇在提高女性性欲方法中的用途,所述方法包括向所述女性给药有效量的雌四醇。口服给药被认为是合适的给药方式。该专利申请记载了与WO2002/094276相同的雌四醇片剂。
WO 2002/094279记载了雌四醇在雌性哺乳动物避孕方法中的用途,该方法包括将所述雌激素组分和孕激素组分以有效量口服给药于有生育能力的女性以抑制排卵。该国际专利申请中记载了用于185mg雌四醇片剂的以下配方。
WO 2003/041718记载了雌四醇在哺乳动物激素替代方法中的用途,该方法包括将雌四醇和孕激素组分以有效量口服给药于哺乳动物以预防或治疗雌激素过少症。该专利申请记载了与WO 2002/094279相同的雌四醇片剂。
WO 2007/081206记载了雌四醇在治疗哺乳动物急性血管疾病的方法中的用途,所述方法包括根据需要将有效量的哺乳动物用雌四醇口服给药于所述哺乳动物。该专利申请记载了硬明胶胶囊的制备,每个胶囊都含有100mg雌四醇和25mg枸橼酸西地那非。
WO 2008/156365记载了雌四醇在治疗新生儿胎粪吸入综合征(MAS)中的用途,所述治疗包括在出生后7天内向所述新生儿给药有效量的雌激素。该国际专利申请记载了用于新生儿的包含至少1μg雌激素的栓剂,所述栓剂的特征还在于最大直径小于10mm,且重量小于0.5g。在栓剂中含有的赋形剂可基于在体温下熔化的脂类材料,或者其可基于在与水接触时溶解或崩解的亲水性组分。
发明内容
本发明提供含有雌四醇组分的口腔分散固体药物剂量单位。剂量单位在含水环境中迅速释放雌四醇。固体剂量单位易于通过直接压制制造并且非常适合于舌下、口腔或唇下给药。舌下、口腔和唇下给药每个都提供如下优点,即雌四醇组分不必经过消化系统并且避免首过肝脏暴露。此外,这些给药方式提供快速起效。
根据本发明的固体剂量单位具有30-1000mg的重量且含有至少100μg的选自雌四醇、雌四醇酯及其组合的雌四醇组分;且由以下组成:
·0.1-25重量%的含有至少80重量%的雌四醇组分的雌四醇颗粒;和
·75-99.9重量%的一种或多种药学上可接受的成分。
该固体剂量单位可通过以下方法获得,所述方法包括:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至50μm;
·通过将所述雌四醇颗粒与一种或多种药学上可接受的成分混合制
备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
对于经由固体剂量单位的舌下、口腔或唇下给药而有效地递送组分而言,将雌四醇组分快速且完全地溶解于唾液中是必不可少的。本发明人已经出乎意料地发现,如果以极小颗粒形式存在于固体剂量单位中,则雌四醇组分被快速释放并分散到唾液中,并且通过口腔的粘膜内层吸收。
本发明还提供制备上述固体剂量单位的方法,所述方法包括以下步骤:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至50μm;
·通过将1重量份的所述雌四醇颗粒与2-1000重量份的一种或多种药学上可接受的赋形剂混合制备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
附图说明
图1图示了实施例3中使用的制造方法流程图。
发明详述
本发明的第一方面涉及重量为30-1000mg的口腔分散固体药物剂量单位,所述剂量单位由以下组成:
·0.1-25重量%的含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒;和
·75-99.9重量%的一种或多种药学上可接受的成分;
所述固体剂量单位包含至少100μg的所述雌四醇组分;
其中所述固体剂量单位可以通过以下方法获得,所述方法包括:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至50μm;
·通过将所述雌四醇颗粒与一种或多种药学上可接受的赋形剂混合制备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
本文所用术语‘雌四醇’是指1,3,5(10)-雌甾三烯-3,15α,16α,17β-四醇或15α-羟雌三醇以及雌四醇水合物,例如雌四醇单水合物。
本文所用术语‘口腔分散剂量单位’是指如下剂量单位,其被设计为当其与唾液接触时在口腔中快速崩解并将雌四醇组分分散到唾液中,使其可通过口腔的粘膜内层吸收。
如下面进一步定义的,本文所用术语‘药学上可接受的成分’包括药学上可接受的赋形剂和除雌四醇组分以外的药学活性成分。
本文所用术语‘舌下’是指通过舌下组织将雌四醇组分扩散到血液中的药理学给药途径。
本文所用术语‘口腔’是指通过口腔前庭的组织,即脸颊内层(口腔粘膜)与牙齿/齿龈之间的口内区域,将雌四醇组分扩散到血液中的药理学给药途径。
本文所用术语‘唇下’是指将雌四醇组分放置在唇和牙龈之间的药理学给药途径。
除非另有说明,否则本文提及的所有百分比均为重量百分比。
本发明所涵盖的固体剂量单位的实例包括片剂、糖衣丸、锭剂和膜剂。根据优选实施方案,剂量单位是片剂,最优选是压制片剂。
固体剂量单位通常具有40-500mg,更优选50-300mg以及最优选70-150mg的重量。
固体剂量单位优选地包含0.5-25重量%,更优选1-20重量%以及最优选1.2-15重量%的雌四醇组分。
在固体剂量单位中含有的雌四醇组分的量优选地在0.3-100mg,更优选0.5-40mg以及最优选1-20mg的范围内。
本发明的雌四醇组分优选选自雌四醇、雌四醇酯(其中至少一个羟基的氢原子已被1-25个碳原子的烃羧酸、磺酸或氨基磺酸的酰基替代)及其组合。甚至更优选地,雌四醇组分是雌四醇(包括雌四醇水合物)。最优选地,在剂量单位中含有的雌四醇组分是雌四醇单水合物。
固体剂量单位中的雌四醇颗粒的粒径应足以在舌下、口腔或唇下给药后实现雌四醇组分的充分吸收。固体剂量单位中的雌四醇颗粒和(独立地)用于制备固体剂量单位的雌四醇颗粒优选具有3-35μm的体积中值直径,更优选4-25μm和最优选5-15μm。
固体剂量单位中的雌四醇颗粒和(独立地)用于制备固体剂量单位的雌四醇颗粒优选含有不超过有限量的粒径超过60μm的颗粒。优选地不超过10体积%的超过60μm(D90),更优选地不超过5体积%的雌四醇颗粒具有超过60μm的粒径(D95)。甚至更优选地,不超过10体积%的超过40μm(D90),更优选地不超过5体积%的雌四醇颗粒具有超过40μm的粒径(D95)。
本发明方法中使用的雌四醇颗粒和其他颗粒材料的粒度分布可借助于激光衍射适当地测定。固体剂量单位内的雌四醇颗粒的粒度分布可以使用光谱技术(如拉曼映射)适当地测定。
本发明的固体剂量单位提供如下优点,即当剂量单位被引入口腔并与唾液接触时,雌四醇组分被迅速释放。雌四醇组分从剂量单位的释放速率可以使用实施例中所述的溶出试验或同样如实施例中所述的根据欧洲药典2.9.1(“片剂和胶囊的崩解”)以及USP<701>(“崩解”)的崩解试验来合适地测定。当进行上述溶出试验时,本发明的固体剂量单位通常在5分钟后释放至少50%,更优选至少70%以及最优选至少80%的雌四醇组分。当进行上述崩解试验时,本发明的固体剂量单位通常在少于5分钟内,更优选在少于2分钟内,还更优选在少于1.5分钟内,还更优选在少于1分钟内,还更优选在少于45秒内以及最优选在少于30秒内崩解。
固体剂量单位中和本发明方法中采用的雌四醇颗粒优选含有至少90重量%的雌四醇组分,更优选至少95重量%的雌四醇组分和最优选至少99重量%的雌四醇组分。除雌四醇组分外,雌四醇颗粒还可以合适地含有药学上可接受的赋形剂,其有助于剂量单位的分散以及雌四醇组分的溶出和吸收。这样的赋形剂的实例包括微晶纤维素、表面活性剂、共溶剂、吸收促进剂、超级崩解剂和缓冲剂。
雌四醇颗粒通常占剂量单位的0.5-35重量%。更优选地,雌四醇颗粒占剂量单位的1-22重量%,最优选地,占剂量单位的1.2-15重量%。
本发明的剂量单位优选地含有50-99.5重量%,更优选55-90重量%和最优选60-88重量%的填充剂,所述填充剂选自麦芽糖、果糖、蔗糖、乳糖、葡萄糖、半乳糖、海藻糖、木糖醇、山梨糖醇、赤藓糖醇、麦芽糖醇、甘露糖醇、异麦芽酮糖醇、微晶纤维素、钙盐(如磷酸钙)及其组合。
根据特别优选的实施方案,剂量单位含有30-99.5重量%,更优选50-90重量%和最优选60-80重量%的填充剂,所述填充剂选自乳糖、木糖醇、山梨糖醇、赤藓糖醇、甘露糖醇、微晶纤维素及其组合。
有利地,剂量单位含有至少20重量%的选自甘露糖醇、木糖醇及其组合的糖醇。更优选地,剂量单位含有30-90重量%的选自甘露糖醇、木糖醇及其组合的糖醇。最优选地,剂量单位含有40-80重量%的选自甘露糖醇、木糖醇及其组合的糖醇。
根据前述权利要求中任一项的剂量单位,其中所述剂量单位含有0.1-20重量%,更优选0.2-10重量%和最优选1-5重量%的崩解剂,所述崩解剂选自改性淀粉(例如羧甲基淀粉的钠盐)、交联聚乙烯吡咯烷酮、交联羧甲基纤维素及其组合。
雌四醇颗粒、填充剂和崩解剂的组合通常构成固体剂量单位的至少70重量%。更优选地,所述组合构成剂量单位的至少80重量%和最优选地至少90重量%。
本发明的固体剂量单位优选含有0-60重量%,更优选5-40重量%和最优选10-35重量%的微晶纤维素。
根据另一个优选的实施方案,剂量单位含有0.1-2重量%,更优选0.2-1.5重量%和最优选0.5-1重量%的润滑剂,所述润滑剂选自硬脂酰富马酸钠、硬脂酸镁、硬脂酸、十二烷基硫酸钠、滑石、聚乙二醇、硬脂酸钙及其混合物。
可合适地掺入剂量单位中的其他赋形剂包括粘膜粘附剂、调味剂、着色剂、甜味剂(除甜味填充剂以外)、助流剂及其组合。
除了雌四醇组分之外,固体剂量单位还可含有一种或多种其它药学活性成分。这样的其它药学活性成分的实例包括类固醇激素。本发明的固体剂量单位优选地含有0.05-10mg,更优选0.1-5mg的一种或多种孕激素,优选一种或多种选自以下的孕激素:孕酮、左炔诺孕酮、诺孕酯、炔诺酮、醋酸炔诺酮(NETA)、地屈孕酮、屈螺酮、3-β-羟基去氧孕烯、3-酮基去氧孕烯(=依托孕烯)、17-去乙酰诺孕酯、19-去甲孕酮、乙酰孕烯醇酮、烯丙雌醇、阿那孕酮、氯地孕酮、环丙孕酮、地美孕酮、去氧孕烯、地诺孕素、二氢孕酮(dihydrogesterone)、地美炔酮、炔孕酮、双醋炔诺醇、醋酸氟孕酮、胃泌素、孕二烯酮、孕三烯酮、羟甲基孕酮、羟孕酮、利奈孕酮(=炔雌烯醇)、美罗孕酮、甲羟基孕酮、甲地孕酮、美仑孕酮、醋酸烯诺孕酮、诺美孕酮、醋酸诺美孕酮(NOMAC)、去甲基脱氢羟孕酮(炔诺酮)、异炔诺酮、甲基炔诺酮(包括d-甲基炔诺酮和dl-甲基炔诺酮)、诺孕烯酮、甲诺酮、孕酮、奎孕醇、(17α)-17-羟基-11-亚甲基-19-去甲孕甾-4,15-二烯-20-炔-3-酮、甲基异炔酮、曲美孕酮、双羟孕酮缩苯乙酮、醋酸烯诺孕酮(nestorone)、普美孕酮、17-羟孕酮酯、19-去甲基-17羟孕酮、17α-乙炔基-睾酮、17α-乙炔基-19-去甲基-睾酮、d-17β-乙酰氧基-13β-乙基-17α-乙炔基-甾烷-4-烯-3-酮肟和这些化合物的前药。优选地,根据本发明使用的一种或多种孕激素选自孕酮、去氧孕烯、依托孕烯、孕二烯酮、地诺孕素、左炔诺孕酮、诺孕酯、炔诺酮、醋酸炔诺酮(NETA)、诺美孕酮、醋酸诺美孕酮(NOMAC)、屈螺酮、曲美孕酮、醋酸烯诺孕酮和地屈孕酮。
根据本发明的固体剂量单位优选地含有0.05-100mg,更优选0.1-50mg的一种或多种雄激素,优选地一种或多种雄激素选自睾酮、脱氢表雄酮(DHEA);DHEA-硫酸盐(DHEAS);睾酮酯(例如十一烷酸睾酮、丙酸睾酮、苯丙酸睾酮、异己酸睾酮、庚酸睾酮、丁酸睾酮(testosterone bucanate)、癸酸睾酮、环甲酸睾酮);甲基睾酮;甲氢睾酮(mesterolon);司坦唑醇;雄烯二酮;双氢睾酮;雄烷二醇;美替诺龙(metenolon);氟羟甲睾酮;羟甲睾酮;美雄酮;MENT和这些化合物的前药。最优选地,一种或多种雄激素选自睾酮、DHEA和MENT。
本发明的另一方面涉及上述固体剂量单位在医学治疗、女性激素替代疗法或女性避孕中的用途,所述用途包括剂量单位的舌下、口腔或唇下给药。其中本发明的固体剂量单位可合适地使用的医学治疗的实例包括骨质疏松症的治疗和子宫内膜异位症、乳腺癌或前列腺癌的雌激素反加治疗。根据优选实施方案,固体剂量单位用于女性激素替代疗法或女性避孕。最优选地,固体剂量用于女性激素替代疗法,特别是用于治疗外阴阴道萎缩和/或血管舒缩症状。
固体剂量单位在医学治疗、女性激素替代疗法或女性避孕中的用途通常包括剂量单位的舌下、口腔或唇下给药,以提供至少0.1mg,更优选0.5-100mg以及最优选1-40mg的雌四醇组分。
为了治疗外阴阴道萎缩,剂量单位优选地以足以提供至少0.1mg的雌四醇组分的量给药。更优选地,给药的剂量单位提供至少0.5mg、最优选至少1mg的雌四醇组分。在外阴阴道萎缩的治疗中,剂量单位优选地以提供不超过50mg,更优选不超过20mg以及最优选不超过10mg的雌四醇组分的量给药。
为了治疗血管舒缩症状,剂量单位优选地以足以提供至少0.2mg的雌四醇组分的量给药。更优选地,给药的剂量单位提供至少1mg、最优选至少2mg的雌四醇组分。在血管舒缩症状的治疗中,剂量单位优选地以提供不超过100mg,更优选不超过40mg以及最优选不超过20mg的雌四醇组分的量给药。
通常,固体剂量单位的这些用途包括在至少1周,更优选至少2周的时段内每日一次给药剂量单位。在这些时段期间,固体剂量单位优选地给药,以提供至少0.05mg,更优选地0.1-40mg以及最优选地0.2-20mg的雌四醇组分的日剂量。
为了治疗外阴阴道萎缩,剂量单位优选地以提供至少0.1mg的雌四醇组分的日剂量给药。更优选地,剂量单位以提供0.5-20mg,最优选1-10mg的雌四醇组分的日剂量给药。
为了治疗血管舒缩症状,剂量单位优选地以提供至少0.2mg的雌四醇组分的日剂量给药。更优选地,剂量单位以提供1-40mg,最优选2-20mg的雌四醇组分的日剂量给药。
本发明的又一方面涉及制备如本文之前所述的固体剂量单位的方法,所述方法包括以下步骤:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至50μm;
·通过将1重量份的所述雌四醇颗粒与2-1000重量份的一种或多种药学上可接受的赋形剂混合制备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
本发明的方法优选不包括在所述雌四醇颗粒和所述一种或多种药学上可接受的赋形剂组合期间或之后加入液体溶剂。
在本发明方法中,优选通过将雌四醇颗粒与一种或多种药学上可接受的赋形剂以1:3至1:500,更优选1:4至1:100和最优选1:5至1:10的重量比组合来产生压制成固体剂量单位的干燥的混合物。
压制成固体剂量单位的干燥的混合物优选含有50-99.5重量%,更优选55-90重量%和最优选60-88重量%的如本文之前所定义的填充剂。
根据特别优选的实施方案,干燥的混合物含有30-99.5重量%,更优选50-90重量%和最优选60-80重量%的填充剂,所述填充剂选自乳糖、木糖醇、山梨糖醇、赤藓糖醇、甘露糖醇、微晶纤维素及其组合。
选自甘露糖醇、木糖醇及其组合的糖醇有利地以至少20重量%的浓度包含在干燥的混合物中。更优选地,所述糖醇以30-90重量%,最优选40-80重量%的浓度包含在干燥的混合物中。
根据另一个优选的实施方案,干燥的混合物含有0.1-20重量%,更优选0.2-10重量%和最优选1-5重量%的崩解剂,所述崩解剂选自改性淀粉、交联聚乙烯吡咯烷酮、交联羧甲基纤维素及其组合。
雌四醇颗粒、填充剂和崩解剂的组合通常构成干燥的混合物的至少70重量%。更优选地,所述组合构成干燥的混合物的至少80重量%和最优选地至少90重量%。
本发明的固体剂量单位优选含有0-60重量%,更优选5-40重量%和最优选10-35重量%的微晶纤维素。
本发明方法中采用的干燥的混合物优选含有0-60重量%,更优选5-40重量%和最优选10-35重量%的微晶纤维素。
压制成固体剂量单位的干燥的混合物优选含有0.1-2重量%,更优选0.2-1.5重量%和最优选0.5-1重量%的润滑剂,所述润滑剂选自硬脂酰富马酸钠、硬脂酸镁、硬脂酸、十二烷基硫酸钠、滑石、聚乙二醇、硬脂酸钙及其混合物。
所述干燥的混合物优选通过直接压制而压制成固体剂量单位。
通过本方法获得的固体剂量单位可以以不同方式来包装。优选地,剂量单位被包装在含有至少14个剂量单位的泡罩包装中。
通过以下非限制性实施例进一步说明本发明。
实施例
溶出试验
下面描述的溶出试验可以用于研究口腔分散剂量单位的溶出行为。
溶出装置
·桨式和篮式溶出测试仪VanKel VK 7010或VK 7025,自动采样器VK 8000,1000mL溶出容器和多孔微米过滤器(35pin)
溶出介质
·将9000ml去矿质水转移到10000ml的容量瓶中。
·加入68.05g的KH2PO4和8.96g的NaOH,并且搅拌溶液直到所有物料溶解。
·混合溶液,并且用NaOH或磷酸将pH值调节至6.8,如有必要,用去矿质水补足体积。
溶出操作
·将900ml的溶出介质转移到桨式装置的每个容器中。
·组装装置,将介质加温至37±0.5℃,然后移去温度计。
·在桨开始旋转之前,在六个容器中的每一个底部放置一片片剂。
·立即开始旋转桨。
·使用50rpm的搅拌速度。
·在5、10、20、30、45、60、75和90分钟后从溶出容器取出5ml样品以获得完全溶出曲线。从溶出介质表面和桨式叶片顶部之间的中间且离容器壁不小于10mm的位置取出样品。除去的溶出体积不被新鲜溶出介质所替代。
使用雌四醇储备溶液作为参照,通过HPLC测定样品中的雌四醇浓度。流动相(MP)磷酸盐缓冲液的制备
·将1.15g的NH4H2PO4(10mM)转移到1000ml去矿质水中,溶解并用磷酸将pH调节至3.0。
HPLC装置
·Alliance 2695分离模块由四元溶剂输送系统、可变容积注射器、温度控制自动采样器、柱恒温器和光电二极管阵列检测器2996(均由Waters提供)组成。
·分析柱:Symmetry C18,3.9×150mm,dp=5μm(例如Waters)
·保护柱:安全保护柱C18,4x3mm(Phenomenex)
·流速:1.0mL/min
·检测:UV@280nm
·柱温:30℃
·自动采样器温度:10℃
·注射体积:100μL
·运行时间:12min
洗脱梯度
时间(min) | 乙腈(%) | 磷酸盐缓冲液(%) |
0 | 20 | 80 |
9 | 75 | 25 |
10 | 20 | 80 |
12 | 20 | 80 |
溶出试验按照一式三份进行。
粒度测量
使用MALVERN MASTERSIZER MICROPLUS激光粒度分析仪进行雌四醇单水合物的粒度分布。
分散介质的制备:
·称取1g雌四醇单水合物和1g脱水山梨醇三油酸酯,加入到烧瓶中。
·加入1升正己烷并在室温下混合至少1小时。
·通过0.45μm过滤器进行过滤。
样品制备:
·将100mg样品放入25mL烧杯中。
·加入几滴分散介质。
·用玻璃棒仔细混合以使粉末充分悬浮。
·加入10mL分散介质。
·在3000-3500rpm的样品分散单位速度下进行分析。
分析:
使用相同分散进行三次粒度测量。通过对三次测定结果进行平均来获得最终结果。
实施例1
通过下面描述的操作制备舌下片剂。
具有表1中所示组成的压片混合物使用低剪切混合机通过干混来制备。
表1
成分 | 重量% |
<![CDATA[研磨雌四醇<sup>1</sup>]]> | 12.5 |
甘露糖醇 | 47.5 |
乳糖 | 30 |
PVP(聚乙烯吡咯烷酮) | 4 |
交联羧甲基纤维素钠 | 4 |
调味剂 | 0.5 |
阿斯巴甜 | 1 |
硬脂酸镁 | 0.5 |
1D(v;0.5)=15μm
将压片混合物压制成直径为6.5mm的80mg圆形片剂。这些片剂的雌四醇含量为10mg。
实施例2
通过下面描述的操作来制备舌下片剂。
具有表2中所示组成的压片混合物使用低剪切混合机通过干混制备。
表2
1D(v;0.5)=15μm
将压片混合物压制成直径为6.5mm的80mg圆形片剂。这些片剂的雌四醇含量为10mg。
实施例3
通过下面描述及图1所示的操作制备5种不同的舌下片剂(制剂A到E)。
每种片剂的雌四醇目标量如下:制剂A为100μg,制剂B为1mg,和制剂C、D和E为10mg。
片剂的目标重量如下:制剂A为30mg,制剂B为1000mg,和制剂C、D和E为80mg。
将雌四醇与主要稀释剂的一部分混合并在800μm筛网上筛分。所有其他赋形剂也在800μm筛网上筛分。
将材料称重并转移至混合容器中(硬脂酸镁除外)混合15分钟。最后加入硬脂酸镁并进一步混合3分钟。
使用配备有合适的冲头(5mm冲头用于30mg片剂(A),6mm冲头用于80mg片剂(C、D和E),和15mm冲头用于1000mg片剂(B))的单冲头机进行压制。
根据欧洲药典2.9.1(“片剂和胶囊的崩解”)以及USP<701>(“崩解”)中的所述已知方案,通过将水用作指定液体,对崩解时间进行定量。
使用欧洲药典2.9.8(“片剂的粉碎阻力”)中所述的已知方案来测量硬度。
最终配方和相应的片剂结果可以在下面的表3和表4中找到。
所有制剂被制备并加工成片剂没有遇到任何具体的困难。应该注意的是,在所有制剂中使用良好的流动性稀释剂以克服流动性问题,并且硬脂酸镁的浓度至少为1.5%以避免粘连。
表3-按重量%计的配方细节
1D(v;0.5)=15μm
表4-实验测定的片剂特征
试验(6个样品的平均结果) | 崩解时间 | 硬度 | 重量 |
制剂# | (min:sec) | (N) | (mg) |
A | 0:53 | 39.57 | 33.22 |
B | 1:07 | 86.07 | 1060.37 |
C | 0:39 | 57.49 | 81.16 |
D | 0:39 | 42.71 | 78.48 |
E | 0:38 | 37.29 | 76.49 |
可以看出,所有片剂获得的最终重量接近其目标重量,并且崩解时间极短(甚至对于最大的1g片剂也是如此),这与预期的这些片剂的舌下、口腔或唇下给药途径相一致。
最后,所有片剂的硬度在非常可接受的范围内。
实施例4
进行随机开放标签的双周期交叉药代动力学研究,来比较在一个100mg片剂中给药的10mg雌四醇的舌下生物利用度与在含有10mg雌四醇的83mg片剂中含有的雌四醇的口服利用度。这些片剂是在禁食条件下舌下和口服给健康女性志愿者。
根据以下标准选择10名健康女性个体:年龄45-65岁(包括端值),不吸烟者或过去吸烟者(给药前至少6个月),体重指数(BMI)=18.5-30kg/m2(筛选时包括端值)。
下表5中描述了100mg舌下片剂的组成。
表5
1D(v;0.5)=15μm
3交联聚维酮超细级
这些片剂具有非常快的崩解时间(平均40秒)。
在研究的第一和第二时段开始时,在上午07:00至上午07:28之间,通过给药一片雌四醇片剂(片剂重量100mg;10mg雌四醇),5名个体接受单剂量的雌四醇舌下制剂,并且通过给药一片雌四醇片剂(片剂重量83mg;10mg雌四醇)并与200ml水一起摄入,5名个体接受单次口服剂量的口服雌四醇制剂。
个体需要在片剂给药前禁食至少10小时,并且在给药后禁食至少4小时。在给药前1小时内不允许饮用水或饮料。片剂给药前1小时和给药后2小时,个体接受200ml的水。片剂给药4小时后,个体可自由饮用水和水果茶。片剂给药前10.5小时以及片剂给药后4、6、9和13小时,提供标准餐。
表6示出了第一和第二时段发生的事件顺序:
表6
表7中示出了本研究中使用的血液和尿液采样时间表。
表7
通过HPLC/MS/MS测定所采集血液样品中的雌四醇浓度。借助于HPLC/MS/MS,也可以测定尿液样品中葡萄糖醛酸苷雌四醇(D-环)的浓度。
这些分析的结果显示,舌下给药的雌四醇的生物利用度与口服给药的雌四醇相当或甚至比其更好。此外,数据表明,与口服给药雌四醇相比,舌下给药的雌四醇具有较早的生物利用度。舌下雌四醇对肝功能参数影响较小。
Claims (26)
1.重量为30-1000mg的口腔分散固体药物剂量单位,所述剂量单位由以下组成:
·0.1-25重量%的含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒;和
·75-99.9重量%的一种或多种药学上可接受的成分;
所述固体剂量单位包含至少100μg的所述雌四醇组分;
其中所述固体剂量单位可以通过以下方法获得,所述方法包括:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至50μm;
·通过将所述雌四醇颗粒与一种或多种药学上可接受的赋形剂混合
制备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
2.如权利要求1所述的剂量单位,其中所述剂量单位的重量为40-500mg。
3.如权利要求1或2所述的剂量单位,其中所述剂量单位含有0.5-25重量%的所述雌四醇组分。
4.如权利要求1或2所述的剂量单位,其中所述剂量单位含有0.3-100mg的所述雌四醇组分。
5.如权利要求1或2所述的剂量单位,其中所述雌四醇组分是雌四醇。
6.如权利要求1或2所述的剂量单位,其中所述雌四醇颗粒的体积中值直径为3-35μm。
7.如权利要求1或2所述的剂量单位,其中所述剂量单位含有50-99.5重量%的填充剂,所述填充剂选自麦芽糖、果糖、蔗糖、乳糖、葡萄糖、半乳糖、海藻糖、木糖醇、山梨糖醇、赤藓糖醇、麦芽糖醇、甘露糖醇、异麦芽酮糖醇、微晶纤维素、钙盐及其组合。
8.如权利要求7所述的剂量单位,其中所述剂量单位含有50-99.5重量%的填充剂,所述填充剂选自乳糖、木糖醇、山梨糖醇、赤藓糖醇、甘露糖醇、微晶纤维素及其组合。
9.如权利要求7所述的剂量单位,其中所述剂量单位含有至少20重量%的选自甘露糖醇、木糖醇及其组合的糖醇。
10.如权利要求1或2所述的剂量单位,其中所述剂量单位含有0.1-20重量%的崩解剂,所述崩解剂选自改性淀粉、交联聚乙烯吡咯烷酮、交联羧甲基纤维素及其组合。
11.如权利要求1或2所述的剂量单位,其中所述剂量单位含有0-60重量%的微晶纤维素。
12.如权利要求1或2所述的剂量单位,其中所述剂量单位含有0.1-2重量%的润滑剂,所述润滑剂选自硬脂酰富马酸钠、硬脂酸镁、硬脂酸、十二烷基硫酸钠、滑石、聚乙二醇、硬脂酸钙及其混合物。
13.雌四醇组分在制备用于医学治疗或用于女性激素替代疗法的药物中的用途,所述药物为权利要求1-12中任一项所述的剂量单位的形式,所述药物用于所述剂量单位的舌下、口腔或唇下给药。
14.如权利要求13所述的用途,所述药物用于在至少1周的时段期间每日一次给药所述剂量单位。
15.雌四醇组分在制备用于女性避孕的药物中的用途,所述药物为根据权利要求1-12中任一项所述的剂量单位的形式,所述药物用于所述剂量单位的舌下、口腔或唇下给药。
16.如权利要求15所述的用途,所述药物用于在至少1周的时段期间每日一次给药所述剂量单位。
17.制备如权利要求1-12中任一项所述的剂量单位的方法,所述方法包括以下步骤:
·提供含有至少80重量%的选自雌四醇、雌四醇酯及其组合的雌四
醇组分的雌四醇颗粒,所述雌四醇颗粒的体积中值直径为2μm至
50μm;
·通过将1重量份的所述雌四醇颗粒与2-1000重量份的一种或多种
药学上可接受的赋形剂混合制备干燥的混合物;和
·将所述干燥的混合物压制成固体剂量单位。
18.如权利要求17所述的方法,其中所述方法不包括在所述雌四醇颗粒和所述一种或多种药学上可接受的赋形剂组合期间或之后加入液体溶剂。
19.如权利要求17或18所述的方法,其中所述雌四醇颗粒的体积中值直径为3-35μm。
20.如权利要求17或18所述的方法,其中所述干燥的混合物含有50-99.5重量%的填充剂,所述填充剂选自麦芽糖、果糖、蔗糖、乳糖、葡萄糖、半乳糖、海藻糖、木糖醇、山梨糖醇、赤藓糖醇、麦芽糖醇、甘露糖醇、异麦芽酮糖醇、微晶纤维素、钙盐及其组合。
21.如权利要求20所述的方法,其中所述剂量单位含有50-99.5重量%的填充剂,所述填充剂选自乳糖、木糖醇、山梨糖醇、赤藓糖醇、甘露糖醇、微晶纤维素及其组合。
22.如权利要求20所述的方法,其中所述干燥的混合物含有至少20重量%的选自甘露糖醇、木糖醇及其组合的糖醇。
23.如权利要求17或18所述的方法,其中所述干燥的混合物含有0.1-20重量%的崩解剂,所述崩解剂选自改性淀粉、交联聚乙烯吡咯烷酮、交联羧甲基纤维素及其组合。
24.如权利要求17或18所述的方法,其中所述剂量单位含有0-60重量%的微晶纤维素。
25.如权利要求17或18所述的方法,其中所述干燥的混合物含有0.1-2重量%的润滑剂,所述润滑剂选自硬脂酰富马酸钠、硬脂酸镁、硬脂酸、十二烷基硫酸钠、滑石、聚乙二醇、硬脂酸钙及其混合物。
26.如权利要求17或18所述的方法,其中所述固体剂量单位通过直接压制而形成。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172747.6 | 2015-06-18 | ||
EP15172747 | 2015-06-18 | ||
CN201680035627.8A CN107771075A (zh) | 2015-06-18 | 2016-06-17 | 含雌四醇组分的口腔分散剂量单位 |
PCT/EP2016/064074 WO2016203011A1 (en) | 2015-06-18 | 2016-06-17 | Orodispersible dosage unit containing an estetrol component |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680035627.8A Division CN107771075A (zh) | 2015-06-18 | 2016-06-17 | 含雌四醇组分的口腔分散剂量单位 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116077454A true CN116077454A (zh) | 2023-05-09 |
Family
ID=53442623
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310318476.9A Pending CN116077454A (zh) | 2015-06-18 | 2016-06-17 | 含雌四醇组分的口腔分散剂量单位 |
CN201680035627.8A Pending CN107771075A (zh) | 2015-06-18 | 2016-06-17 | 含雌四醇组分的口腔分散剂量单位 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680035627.8A Pending CN107771075A (zh) | 2015-06-18 | 2016-06-17 | 含雌四醇组分的口腔分散剂量单位 |
Country Status (42)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2714710T3 (pl) | 2011-06-01 | 2017-03-31 | Estetra S.P.R.L. | Sposób wytwarzania estetrolowych związków pośrednich |
KR101957937B1 (ko) | 2011-06-01 | 2019-03-14 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
SI3310346T1 (sl) | 2015-06-18 | 2021-07-30 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
CA2988498C (en) | 2015-06-18 | 2022-02-08 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
JP6866561B2 (ja) | 2015-06-18 | 2021-04-28 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロールを含有する口腔内崩壊錠 |
RS62844B1 (sr) | 2015-06-18 | 2022-02-28 | Estetra Srl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TWI801561B (zh) * | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094276A1 (en) * | 2001-05-18 | 2002-11-28 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
CA1306950C (en) | 1987-04-10 | 1992-09-01 | Alec D. Keith | Buccal administration of estrogens |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
GB2228412B (en) | 1989-02-28 | 1993-04-14 | Syntex Inc | Nicardipine pharmaceutical composition for parenteral administration |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
FR2772272B1 (fr) | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
CN100379407C (zh) | 1997-12-19 | 2008-04-09 | 史密丝克莱恩比彻姆公司 | 生产咀嚼分散片的方法 |
US7815937B2 (en) | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
TW548277B (en) | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
ATE317396T1 (de) | 1999-12-02 | 2006-02-15 | Akzo Nobel Nv | 14,15-beta-methylen substituierte androgene |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
PT1293210E (pt) * | 2001-05-23 | 2004-04-30 | Pantarhei Bioscience Bv | Dispositivo e metodo anticoncepcional hormonal |
US20020193356A1 (en) | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
EP1390042B1 (en) | 2001-05-23 | 2007-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
CA2448273C (en) | 2001-05-23 | 2010-06-29 | Christian Franz Holinka | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
DK1446128T3 (da) * | 2001-11-15 | 2007-04-02 | Pantarhei Bioscience Bv | Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
NZ534806A (en) | 2002-02-21 | 2006-05-26 | Schering Ag | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12 |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
PT1511496E (pt) | 2002-06-11 | 2007-01-31 | Pantarhei Bioscience Bv | Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas |
US7943604B2 (en) | 2002-06-11 | 2011-05-17 | Pantarhei Bioscience B.V. | Method of treating human skin and a skin care composition for use in such a method |
DK1526856T3 (da) | 2002-07-12 | 2008-03-10 | Pantarhei Bioscience Bv | Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi |
KR20050059092A (ko) | 2002-08-28 | 2005-06-17 | 로버트 캐스퍼 | 에스트로겐 보충 요법 |
DK1556058T3 (da) | 2002-10-23 | 2008-03-03 | Pantarhei Bioscience Bv | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi |
ES2338781T3 (es) | 2002-11-05 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Uso de la drospirenona para el tratamiento de una hipertension. |
AU2003279624A1 (en) | 2002-11-08 | 2004-06-07 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
PT1624878E (pt) | 2003-05-22 | 2007-01-31 | Pantarhei Bioscience Bv | Utilização de composições que compreendem um componente estrogénico para o tratamento e prevenção da dor musculoesquelética |
DK1670440T3 (da) | 2003-09-29 | 2014-07-07 | Novo Nordisk As | HRT formuleringer |
AU2004275470B2 (en) | 2003-09-29 | 2010-12-02 | Novo Nordisk Health Care Ag | Improved stability of progestogen formulations |
JP3841804B2 (ja) | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
PL1755562T3 (pl) | 2004-05-28 | 2014-03-31 | Richter Gedeon Nyrt | Środek antykoncepcyjny zawierający kwas foliowy |
ATE424814T1 (de) | 2004-07-01 | 2009-03-15 | Lek Pharmaceuticals | Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose |
UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
US8808735B2 (en) | 2005-02-03 | 2014-08-19 | Takeda Nycomed As | Fast wet-massing method for the preparation of calcium-containing compositions |
IS7724A (is) | 2005-03-02 | 2006-09-03 | Actavis Group | Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat |
UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
RU2412196C2 (ru) | 2005-05-26 | 2011-02-20 | Зольвай Фармасьютиклз Гмбх | ИНГИБИТОРЫ 17β-ГСД1 И СТС |
US20070048369A1 (en) * | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
ATE481973T1 (de) * | 2006-01-09 | 2010-10-15 | Pantarhei Bioscience Bv | Verfahren zur behandlung einer akuten gefässerkrankung |
WO2007106264A2 (en) | 2006-03-02 | 2007-09-20 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20070286819A1 (en) * | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
ES2659316T3 (es) * | 2006-06-08 | 2018-03-14 | Allergan Pharmaceuticals International Limited | Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada |
CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
JP2009542588A (ja) | 2006-07-06 | 2009-12-03 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 避妊及び先天的異常の危険性の予防のための医薬製剤 |
RU2009117201A (ru) | 2006-11-29 | 2011-01-10 | Вайет (Us) | Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина |
EP2124900B1 (en) | 2006-12-20 | 2014-12-03 | Teva Women's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
EP2114412B1 (en) | 2007-01-08 | 2010-07-14 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
BRPI0806543A2 (pt) | 2007-01-12 | 2014-04-22 | Wyeth Corp | Composições de comprimido em comprimido |
EP1972618A1 (en) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
ES2378117T3 (es) | 2007-06-21 | 2012-04-09 | Pantarhei Bioscience B.V. | Tratamiento del Síndrome de aspiración de meconio con estrógenos |
CA2693982C (en) | 2007-07-19 | 2017-03-14 | Pantarhei Bioscience B.V. | Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation |
FR2920311B1 (fr) | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
JP5399749B2 (ja) | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
CN101780073B (zh) | 2009-01-21 | 2013-07-03 | 重庆圣华曦药业股份有限公司 | 非布司他分散片药物及其制备方法 |
EP2210591B1 (en) | 2009-01-26 | 2016-03-30 | Shin-Etsu Chemical Co., Ltd. | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
WO2010109019A1 (en) | 2009-03-26 | 2010-09-30 | Royal College Of Surgeons In Ireland | Orodispersible tablets |
MX2011013959A (es) | 2009-06-23 | 2012-01-25 | Bayer Pharma AG | Composicion farmaceutica para la anticoncepcion de emergencia. |
ITMI20091109A1 (it) | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
EP2399904A1 (en) | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
US20120282335A1 (en) | 2010-12-02 | 2012-11-08 | Aptalis Pharmatech Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
JP2012240917A (ja) | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | 製剤化用微粒子とそれを含む製剤 |
PL2714710T3 (pl) | 2011-06-01 | 2017-03-31 | Estetra S.P.R.L. | Sposób wytwarzania estetrolowych związków pośrednich |
KR101957937B1 (ko) | 2011-06-01 | 2019-03-14 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
RU2627111C2 (ru) | 2011-07-19 | 2017-08-03 | Пантархей Байосайенс Б.В. | Таблетка, содержащая дегидроэпиандростерон (дгэа) |
EA028780B1 (ru) | 2011-08-11 | 2017-12-29 | Эстетра С.П.Р.Л. | Применение эстетрола в качестве экстренного контрацептива |
NZ620897A (en) | 2011-09-16 | 2016-07-29 | Ferring Bv | A fast dissolving pharmaceutical composition |
SG11201401282PA (en) | 2011-10-07 | 2014-05-29 | Estetra Sprl | Process for the production of estetrol |
DE202012012822U1 (de) | 2011-12-13 | 2014-02-03 | Arstat, Inc. | Empfängnisverhütungs-Set zur aufeinanderfolgenden täglichen Anwendung |
EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
US9238265B2 (en) | 2012-09-27 | 2016-01-19 | General Electric Company | Backstrike protection during machining of cooling features |
JP6126456B2 (ja) | 2013-05-17 | 2017-05-10 | 東和薬品株式会社 | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 |
AU2014268779A1 (en) | 2013-05-21 | 2016-01-21 | Predictive Therapeutics, LLC | Therapeutic and method of use |
CA2924255C (en) | 2013-09-18 | 2022-11-22 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
US20150098978A1 (en) | 2013-10-03 | 2015-04-09 | Altria Client Services Inc. | Dissolvable-chewable tablet |
JP6447931B2 (ja) | 2013-12-12 | 2019-01-09 | ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. | エステトロール成分を含有する口腔内崩壊固体単位剤形 |
ES2957543T3 (es) | 2014-09-29 | 2024-01-22 | Univ California | Composiciones y métodos para mantener la función cognitiva |
BR112017024783A2 (pt) | 2015-05-18 | 2018-08-07 | Agile Therapeutics Inc | composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais |
SI3310346T1 (sl) | 2015-06-18 | 2021-07-30 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
JP6866561B2 (ja) | 2015-06-18 | 2021-04-28 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロールを含有する口腔内崩壊錠 |
CA2988498C (en) | 2015-06-18 | 2022-02-08 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
RS62844B1 (sr) | 2015-06-18 | 2022-02-28 | Estetra Srl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
SI3313408T1 (sl) | 2015-06-23 | 2024-04-30 | Laboratorios Leon Farma Sa | Kontraceptiv na osnovi drospirenona za pacientko s prekomerno težo |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
US20200046729A1 (en) | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
KR20190076014A (ko) | 2016-10-28 | 2019-07-01 | 에스테트라 에스.피.알.엘. | 월경통 및 생리통의 관리방법 |
EP4140489A1 (en) | 2018-02-07 | 2023-03-01 | Estetra SRL | Contraceptive composition with reduced cardiovascular effects |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
TW202203935A (zh) | 2020-04-16 | 2022-02-01 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
-
2016
- 2016-06-17 CA CA2988498A patent/CA2988498C/en active Active
- 2016-06-17 ES ES16175091.4T patent/ES2671160T3/es active Active
- 2016-06-17 SI SI201630043T patent/SI3106148T1/en unknown
- 2016-06-17 WO PCT/EP2016/064074 patent/WO2016203011A1/en active Application Filing
- 2016-06-17 CU CU2017000159A patent/CU24523B1/es unknown
- 2016-06-17 GE GEAP201614677A patent/GEP20217308B/en unknown
- 2016-06-17 UA UAA201800473A patent/UA123098C2/uk unknown
- 2016-06-17 PL PL16175091T patent/PL3106148T3/pl unknown
- 2016-06-17 NZ NZ737948A patent/NZ737948A/en unknown
- 2016-06-17 HU HUE16175091A patent/HUE037383T2/hu unknown
- 2016-06-17 MX MX2017016276A patent/MX2017016276A/es unknown
- 2016-06-17 DK DK16175091.4T patent/DK3106148T3/en active
- 2016-06-17 JP JP2017564097A patent/JP6863547B2/ja active Active
- 2016-06-17 TR TR2018/08438T patent/TR201808438T4/tr unknown
- 2016-06-17 MY MYPI2017001862A patent/MY195019A/en unknown
- 2016-06-17 NO NO16175091A patent/NO3106148T3/no unknown
- 2016-06-17 PE PE2017002731A patent/PE20180398A1/es unknown
- 2016-06-17 RS RS20180661A patent/RS57328B1/sr unknown
- 2016-06-17 AU AU2016280863A patent/AU2016280863B2/en active Active
- 2016-06-17 TN TNP/2017/000499A patent/TN2017000499A1/en unknown
- 2016-06-17 KR KR1020187001723A patent/KR102664563B1/ko active IP Right Grant
- 2016-06-17 CN CN202310318476.9A patent/CN116077454A/zh active Pending
- 2016-06-17 EP EP16175091.4A patent/EP3106148B1/en active Active
- 2016-06-17 CR CR20180042A patent/CR20180042A/es unknown
- 2016-06-17 EA EA201890084A patent/EA035651B1/ru unknown
- 2016-06-17 PT PT161750914T patent/PT3106148T/pt unknown
- 2016-06-17 LT LTEP16175091.4T patent/LT3106148T/lt unknown
- 2016-06-17 US US15/185,337 patent/US20160367567A1/en not_active Abandoned
- 2016-06-17 CN CN201680035627.8A patent/CN107771075A/zh active Pending
- 2016-06-17 SG SG10202010432UA patent/SG10202010432UA/en unknown
-
2017
- 2017-12-06 ZA ZA2017/08287A patent/ZA201708287B/en unknown
- 2017-12-11 DO DO2017000293A patent/DOP2017000293A/es unknown
- 2017-12-12 IL IL256283A patent/IL256283B/en active IP Right Grant
- 2017-12-13 CO CONC2017/0012766A patent/CO2017012766A2/es unknown
- 2017-12-14 GT GT201700270A patent/GT201700270A/es unknown
- 2017-12-14 SA SA517390550A patent/SA517390550B1/ar unknown
- 2017-12-14 CL CL2017003208A patent/CL2017003208A1/es unknown
- 2017-12-15 SV SV2017005595A patent/SV2017005595A/es unknown
- 2017-12-15 PH PH12017502325A patent/PH12017502325B1/en unknown
- 2017-12-29 EC ECIEPI201785669A patent/ECSP17085669A/es unknown
-
2018
- 2018-05-14 CY CY20181100490T patent/CY1120467T1/el unknown
- 2018-06-06 HR HRP20180889TT patent/HRP20180889T1/hr unknown
- 2018-07-02 US US16/025,719 patent/US10660903B2/en active Active
- 2018-09-03 HK HK18111269.1A patent/HK1251940A1/zh unknown
-
2020
- 2020-05-26 US US16/883,052 patent/US11957694B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094276A1 (en) * | 2001-05-18 | 2002-11-28 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
WO2014159377A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
Non-Patent Citations (3)
Title |
---|
ROYALHANSON等: "《溶出度试验技术第3版》", 30 November 2007, 中国医药科技出版社, pages: 66 * |
刘蜀宝: "《药剂学》", 31 July 2007, 河南科学技术出版社, pages: 153 * |
罗恋梅等: "雌四醇的研究进展", 《生殖医学杂志》, vol. 18, no. 3, 30 June 2009 (2009-06-30), pages 305 - 308 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022283615B2 (en) | Orodispersible dosage unit containing an estetrol component | |
US11957694B2 (en) | Orodispersible dosage unit containing an estetrol component | |
CN107750157B (zh) | 含雌四醇的口腔分散片剂 | |
EP3079671B1 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
US10894014B2 (en) | Orodispersible tablet containing Estetrol | |
OA18501A (en) | Orodispersible dosage unit containing an estetrol component. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40087928 Country of ref document: HK |